Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting

Myelodysplastic Syndrome: An Update from ASCO 2007

Advances in the Treatment of Myelodysplastic Syndrome: Report from the 2006 American Society of Hematology Meeting

Treating Malignant Disease With Reduced Intensity Stem Cell Transplants - A Review

Vidaza® Improves Survival of Higher-Risk Myelodysplastic Syndromes (MDS) (1/2/2008)
Researchers affiliated with the AZA-001 study have reported that Vidaza (azacitadine) prolongs survival of patients with higher risk myelodysplastic syndrome (MDS). The details of this randomized study were presented at the 2007 meeting of the American Society of Hematology in Atlanta, Georgia in December.

Romiplostim (AMG 531) for Treatment of Thrombocytopenia in MDS (12/27/2007)
Researchers affiliated with The AMG 531 Myelodysplastic Syndrome Study Group have reported that romiplostim (AMG531) can reduce bleeding and transfusion events in patients with myelodysplastic syndromes (MDS). The details of this study were presented at the 2007 meeting of the American Society of Hematology (ASH), December 8-11, 2007 in Atlanta, Georgia.

Umbilical Cord Blood Transplantation with Reduced Intensity Regimen Effective (11/14/2007)
Researchers from the University of Minnesota have reported that adults with hematological diseases have a three year survival of almost 50% following umbilical cord blood transplantation after a reduced intensity treatment regimen. The details of this study appeared in the October 15, 2007 issue of Blood.

Vidaza® Significantly Improves Survival in MDS (8/6/2007)
Researchers involved in a multi-center international trial have reported that Vidaza (5-azacitadine) improves survival in patients with myelodysplastic syndromes (MDS). The preliminary details of this study were announced at a news conference on 8/3/07 and details can be accessed on the Pharmion website. The final report of these data will be submitted for presentation at the 2007 meeting of the American Society of Hematology in December of 2007. 

AMG 531 Maybe Effective in Treating Thrombocytopenia in Patients with MDS (6/11/2007)
Researchers affiliated with The AMG 531 in Myelodysplastic Syndrome Study Group have reported that AMG 531 can reduce bleeding and transfusion events in patients with myelodysplastic syndromes (MDS). The details of this study were presented at the 2007 meeting of the American Society of Clinical Oncology in June.